（原标题：非洲疾病预防控制中心欢迎首款专为婴儿配制的疟疾治疗药物，称其为"重大进展"） 非洲疾病预防控制中心还赞扬了试用该药物的八个成员国，包括布基纳法索、科特迪瓦、肯尼亚、 马拉维、莫桑比克、尼日利亚、坦桑尼亚和乌干达。这种新疗法预计将在几周内在八个非洲试验国推 行。非洲疾病预防控制中心表示将继续与相关成员国合作，确保每个儿童都能获得治疗。根据世界卫生 组织（WHO）的最新数据，2023年疟疾导致全球59.7万人死亡，其中几乎全部集中在非洲大陆。世卫 组织称，5岁以下儿童约占非洲疟疾死亡总人数的76%。 "africanews"网站8月18日报道，非洲疾病控制和预防中心（Africa CDC）对首款专为婴儿配制的疟 疾治疗药物获得批准表示欢迎，称其是"在缩小非洲最年幼和最脆弱人群的护理差距方面取得的重大进 展"。这种名为Coartem Baby的新疗法专门用于体重不足五公斤的新生儿和婴儿，由瑞士制药公司诺华 和非营利性组疟疾新药研发（Medicines for Malaria Venture）合作开发。瑞士药品监管机构于今年7月批 准了这一配方。非洲疾病预防控制中心称，由于缺乏专门的治疗方法，迄今为止，一直 ...

Group 1 - The Swiss Medicines Agency has approved Novartis' Riamet Baby, a new anti-malaria drug specifically designed for newborns weighing between 2 to 5 kilograms, marking a significant advancement in the global fight against malaria [1] - Riamet Baby can dissolve in breast milk and has a sweet cherry flavor, making it easier for newborns to consume [1] - Prior to the approval of Riamet Baby, there were no approved treatments for malaria in newborns weighing less than 4.5 kilograms, which posed risks of overdose and increased toxicity when using formulations intended for older children [1] Group 2 - The approval process involved close collaboration with drug regulatory agencies from eight African countries, including Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Uganda, and Tanzania [1] - The World Health Organization's Global Malaria Program participated in the scientific evaluation of Riamet Baby [1] - According to the WHO's 2024 World Malaria Report, 94% of malaria cases and 95% of malaria deaths in 2023 occurred in the African region, with 76% of deaths being children under five years old [2]